Based on what was agreed to under the Biosimilar User Fee Amendments (BsUFA III), FDA estimated that its base revenue from the program for FY 2027 needs to bring in $58,926,749 before being adjusted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results